Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option
雷莫芦单抗联合FOLFIRI或伊立替康作为胃食管腺癌患者的二线治疗:一项新兴治疗方案的综述和荟萃分析
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2024.1419338
Park, Haeseong; Klempner, Samuel J; Chao, Joseph; Wainberg, Zev A; Lukanowski, Mariusz; Chenji, Suresh; Bourke, Shannon; Chatterjee, Anindya; Lorenzen, Sylvie